Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

to evaluate the efficacy and safety of EYLEA in the treatment of diabetic macular edema (DME).  Both studies are fully enrolled.  In February 2013, Bayer HealthCare initiated another Phase 3 DME trial, VIVID EAST-DME, in Russia, China, and other Asian countries.
  • The VIBRANT study of EYLEA in macular edema following branch retinal vein occlusion (BRVO) is now fully enrolled.
  • ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion

  • The Company and Sanofi collaborate on the global development and commercialization of ZALTRAP, and share profits and losses from commercialization of ZALTRAP except for Japan, where the Company will receive a royalty on sales. 
  • In February 2013, the European Commission (EC) granted marketing authorization in the European Union for ZALTRAP concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.  Marketing authorization applications for ZALTRAP are also currently under review by other regulatory agencies worldwide.
  • In the first quarter of 2013, Sanofi recorded worldwide net sales of ZALTRAP of $14 million.  
  • Monoclonal Antibodies

  • Regeneron has eleven fully human monoclonal antibodies based on the Company's VelocImmune® technology in clinical development, including six in collaboration with Sanofi.
  • ODYSSEY, a large, global Phase 3 program with alirocumab (REGN727), an antibody targeting PCSK9 to reduce LDL cholesterol, was initiated in June 2012 and is currently enrolling patients.  The Company expects to report initial results from a Phase 3 ODYSSEY trial in the second half of 2013.  Alirocumab is being developed in collaboration with Sanofi.
  • Positive proof of concept data from two Phase
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Regeneron Announces March 2012 Investor Conference Presentations
    5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
    8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
    10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
    11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
    (Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
    (Date:7/29/2014)... The first product launch from start-up Hurley Research ... What sets Droidles completely apart from other stand alone ... to communicate, share code with each other and evolve ... invention is the system,” said Hurley Research founder Jay ... their own, both physically and on the internet." Remote ...
    (Date:7/29/2014)... July 29, 2014 The prestigious "Discovery ... Congress was recently awarded to Juliana Hillis and Kaylie ... for their project, “From an Egg, Everything: America’s First ... final entries for the National History Day program during ... historians and educators in Washington, D.C. , The growing ...
    Breaking Biology Technology:DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
    ... Epitomics, Inc. today announced that The Michael J. ... company to distribute a panel of LRRK2 monoclonal antibodies ... parties. Under a special arrangement the antibodies are being ... community to help advance LRRK2 therapeutic development efforts. The ...
    ... BASEL, Switzerland, Sept. 17 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEETS: ... Poulin as President and CEO. Mr Barry ... the Company,s direction during the summer of 2010, I ... in order to facilitate the transition process, and now ...
    ... 2010 bluebird bio (formerly Genetix Pharmaceuticals Inc.) an ... for severe genetic disorders, today announced publication in the ... data highlighting positive results of LentiGlobin gene therapy treatment ... disorder that is one of the most frequent inherited ...
    Cached Biology Technology:Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp. 2Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study 2Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study 3
    (Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
    (Date:7/29/2014)... research from scientists at the University of Kent has ... cells are regulated a breakthrough that could have ... team from Kent,s School of Biosciences uncovered the mechanism ... cells known as actin filaments are ,fine-tuned, ... actin filaments appear to completely stable, providing a framework ...
    (Date:7/29/2014)... rare disease it affects 1 in 100,000 people ... wall. While its cause remains unknown, a new study by ... University of Bonn in Germany and other European institutions confirms ... The study, published on 6 July in Nature Genetics ... , When we swallow, a sphincter in the lower esophagus ...
    Breaking Biology News(10 mins):Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2Mysterious esophagus disease is autoimmune after all 2
    ... CHICAGO, Ill. (March 29, 2011)A medical device developed by ... a new paradigm for the detection, diagnosis and monitoring ... the Society of Interventional Radiology,s 36th Annual Scientific Meeting ... trauma is detected, identified and located using a simple ...
    ... global economy depends on marine transportation. But in addition ... stowaways that can cause huge problems for the environment ... will facilitate accurate screening of vessels for dangerous species ... in the journal Environmental Science & Technology . ...
    ... A novel supercomputing resource created by researchers at the ... San Diego, is allowing scientists to study evolutionary relationships ... times and without having to understand how to ... new resource, called the CIPRES (Cyberinfrastructure for Phylogenetic RESearch) ...
    Cached Biology News:New device uses submarine technology to diagnose stroke quickly 2New device uses submarine technology to diagnose stroke quickly 3Smithsonian scientists help block ship-borne bioinvaders before they dock 2Smithsonian scientists help block ship-borne bioinvaders before they dock 3SDSC's CIPRES Gateway provides window to the past -- and fast 2SDSC's CIPRES Gateway provides window to the past -- and fast 3
    Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
    The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
    ... solution. Cleaves a-(1-3)- and ... and glycoproteins. It is particularly efficient for ... pH must be neutral or above, for ... Unit Definition: One unit will hydrolyze ...
    ... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
    Biology Products: